Blood samples were drawn from 3 animals/time point at predose (time 0), 2, 5, 10, 20, 40 minutes, 1, 2, 3, and 4 hours. Plasma samples were analyzed for content of rFVIIa and FVIIa_IIa, K337A-FVIIa_IIa, and M298Q-FVIIa, and the following parameters were estimated: terminal plasma elimination half-life (t_1/2), based on the natural logarithm of 2 divided by the slope of the log-linear regression of the concentration versus time (λ_z). The total body clearance (CL) was determined as dose divided by area under the plasma concentration curve (AUC) from zero to infinity. The volume of distribution based on the terminal phase (V_z) was estimated by dose divide by AUC times λ_z. The clearance and volume of distribution (V_z) was higher for the analogs than for rFVIIa, increasing in the order FVIIa < M298Q-FVIIa < K337A-FVIIa_IIa < FVIIa_IIa. A comparison of these parameters at the same dose of rFVIIa and rFVIIa analogs reveals approximately a 2- to 3-fold increase of the values obtained for the analogs. All mice treated with either rFVIIa or one of the 3 analogs were exposed to the drug up to 4 hours after dosage.